Report Thumbnail
Product Code LP0915210472YLY
Published Date 2023/2/27
English102 PagesGlobal

Global CAR-T Therapy Market Growth (Status and Outlook) 2023-2029Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code LP0915210472YLY◆The Feb 2026 edition is also likely available. We will check with the publisher immediately.
Published Date 2023/2/27
English 102 PagesGlobal

Global CAR-T Therapy Market Growth (Status and Outlook) 2023-2029Pharmaceutical_LifeSciense Market



Abstract


Summary

LPI (LP Information)' newest research report, the “CAR-T Therapy Industry Forecast” looks at past sales and reviews total world CAR-T Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected CAR-T Therapy sales for 2023 through 2029. With CAR-T Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CAR-T Therapy industry.
This Insight Report provides a comprehensive analysis of the global CAR-T Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on CAR-T Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global CAR-T Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CAR-T Therapy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CAR-T Therapy.
The global CAR-T Therapy market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for CAR-T Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for CAR-T Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for CAR-T Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key CAR-T Therapy players cover Novartis AG, Kite Pharma, Pfizer, Juno Therapeutics, Celgene Corporation, CARsgen Therapeutics, Sorrento Therapeutics, Legend Biotech and Atara Biotherapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of CAR-T Therapy market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
CD19
CD22
Other
Segmentation by application
Acute Lymphocytic Leukemia
Diffuse Large B Cell Lymphoma
Follicular Lymphoma
Chronic Lymphocytic Leukemia
Multiple Myeloma
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis AG
Kite Pharma
Pfizer
Juno Therapeutics
Celgene Corporation
CARsgen Therapeutics
Sorrento Therapeutics
Legend Biotech
Atara Biotherapeutics
Aurora Biopharma
Autolus Therapeutics PLC
Bluebird
Carina Biotech

Table of Contents

  • 1 Scope of the Report

    • 1.1 Market Introduction
    • 1.2 Years Considered
    • 1.3 Research Objectives
    • 1.4 Market Research Methodology
    • 1.5 Research Process and Data Source
    • 1.6 Economic Indicators
    • 1.7 Currency Considered
    • 1.8 Market Estimation Caveats
  • 2 Executive Summary

    • 2.1 World Market Overview
      • 2.1.1 Global CAR-T Therapy Market Size 2018-2029
      • 2.1.2 CAR-T Therapy Market Size CAGR by Region 2018 VS 2022 VS 2029
    • 2.2 CAR-T Therapy Segment by Type
      • 2.2.1 CD19
      • 2.2.2 CD22
      • 2.2.3 Other
    • 2.3 CAR-T Therapy Market Size by Type
      • 2.3.1 CAR-T Therapy Market Size CAGR by Type (2018 VS 2022 VS 2029)
      • 2.3.2 Global CAR-T Therapy Market Size Market Share by Type (2018-2023)
    • 2.4 CAR-T Therapy Segment by Application
      • 2.4.1 Acute Lymphocytic Leukemia
      • 2.4.2 Diffuse Large B Cell Lymphoma
      • 2.4.3 Follicular Lymphoma
      • 2.4.4 Chronic Lymphocytic Leukemia
      • 2.4.5 Multiple Myeloma
      • 2.4.6 Other
    • 2.5 CAR-T Therapy Market Size by Application
      • 2.5.1 CAR-T Therapy Market Size CAGR by Application (2018 VS 2022 VS 2029)
      • 2.5.2 Global CAR-T Therapy Market Size Market Share by Application (2018-2023)
  • 3 CAR-T Therapy Market Size by Player

    • 3.1 CAR-T Therapy Market Size Market Share by Players
      • 3.1.1 Global CAR-T Therapy Revenue by Players (2018-2023)
      • 3.1.2 Global CAR-T Therapy Revenue Market Share by Players (2018-2023)
    • 3.2 Global CAR-T Therapy Key Players Head office and Products Offered
    • 3.3 Market Concentration Rate Analysis
      • 3.3.1 Competition Landscape Analysis
      • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
    • 3.4 New Products and Potential Entrants
    • 3.5 Mergers & Acquisitions, Expansion
  • 4 CAR-T Therapy by Regions

    • 4.1 CAR-T Therapy Market Size by Regions (2018-2023)
    • 4.2 Americas CAR-T Therapy Market Size Growth (2018-2023)
    • 4.3 APAC CAR-T Therapy Market Size Growth (2018-2023)
    • 4.4 Europe CAR-T Therapy Market Size Growth (2018-2023)
    • 4.5 Middle East & Africa CAR-T Therapy Market Size Growth (2018-2023)
  • 5 Americas

    • 5.1 Americas CAR-T Therapy Market Size by Country (2018-2023)
    • 5.2 Americas CAR-T Therapy Market Size by Type (2018-2023)
    • 5.3 Americas CAR-T Therapy Market Size by Application (2018-2023)
    • 5.4 United States
    • 5.5 Canada
    • 5.6 Mexico
    • 5.7 Brazil
  • 6 APAC

    • 6.1 APAC CAR-T Therapy Market Size by Region (2018-2023)
    • 6.2 APAC CAR-T Therapy Market Size by Type (2018-2023)
    • 6.3 APAC CAR-T Therapy Market Size by Application (2018-2023)
    • 6.4 China
    • 6.5 Japan
    • 6.6 Korea
    • 6.7 Southeast Asia
    • 6.8 India
    • 6.9 Australia
  • 7 Europe

    • 7.1 Europe CAR-T Therapy by Country (2018-2023)
    • 7.2 Europe CAR-T Therapy Market Size by Type (2018-2023)
    • 7.3 Europe CAR-T Therapy Market Size by Application (2018-2023)
    • 7.4 Germany
    • 7.5 France
    • 7.6 UK
    • 7.7 Italy
    • 7.8 Russia
  • 8 Middle East & Africa

    • 8.1 Middle East & Africa CAR-T Therapy by Region (2018-2023)
    • 8.2 Middle East & Africa CAR-T Therapy Market Size by Type (2018-2023)
    • 8.3 Middle East & Africa CAR-T Therapy Market Size by Application (2018-2023)
    • 8.4 Egypt
    • 8.5 South Africa
    • 8.6 Israel
    • 8.7 Turkey
    • 8.8 GCC Countries
  • 9 Market Drivers, Challenges and Trends

    • 9.1 Market Drivers & Growth Opportunities
    • 9.2 Market Challenges & Risks
    • 9.3 Industry Trends
  • 10 Global CAR-T Therapy Market Forecast

    • 10.1 Global CAR-T Therapy Forecast by Regions (2024-2029)
      • 10.1.1 Global CAR-T Therapy Forecast by Regions (2024-2029)
      • 10.1.2 Americas CAR-T Therapy Forecast
      • 10.1.3 APAC CAR-T Therapy Forecast
      • 10.1.4 Europe CAR-T Therapy Forecast
      • 10.1.5 Middle East & Africa CAR-T Therapy Forecast
    • 10.2 Americas CAR-T Therapy Forecast by Country (2024-2029)
      • 10.2.1 United States CAR-T Therapy Market Forecast
      • 10.2.2 Canada CAR-T Therapy Market Forecast
      • 10.2.3 Mexico CAR-T Therapy Market Forecast
      • 10.2.4 Brazil CAR-T Therapy Market Forecast
    • 10.3 APAC CAR-T Therapy Forecast by Region (2024-2029)
      • 10.3.1 China CAR-T Therapy Market Forecast
      • 10.3.2 Japan CAR-T Therapy Market Forecast
      • 10.3.3 Korea CAR-T Therapy Market Forecast
      • 10.3.4 Southeast Asia CAR-T Therapy Market Forecast
      • 10.3.5 India CAR-T Therapy Market Forecast
      • 10.3.6 Australia CAR-T Therapy Market Forecast
    • 10.4 Europe CAR-T Therapy Forecast by Country (2024-2029)
      • 10.4.1 Germany CAR-T Therapy Market Forecast
      • 10.4.2 France CAR-T Therapy Market Forecast
      • 10.4.3 UK CAR-T Therapy Market Forecast
      • 10.4.4 Italy CAR-T Therapy Market Forecast
      • 10.4.5 Russia CAR-T Therapy Market Forecast
    • 10.5 Middle East & Africa CAR-T Therapy Forecast by Region (2024-2029)
      • 10.5.1 Egypt CAR-T Therapy Market Forecast
      • 10.5.2 South Africa CAR-T Therapy Market Forecast
      • 10.5.3 Israel CAR-T Therapy Market Forecast
      • 10.5.4 Turkey CAR-T Therapy Market Forecast
      • 10.5.5 GCC Countries CAR-T Therapy Market Forecast
    • 10.6 Global CAR-T Therapy Forecast by Type (2024-2029)
    • 10.7 Global CAR-T Therapy Forecast by Application (2024-2029)
  • 11 Key Players Analysis

    • 11.1 Novartis AG
      • 11.1.1 Novartis AG Company Information
      • 11.1.2 Novartis AG CAR-T Therapy Product Offered
      • 11.1.3 Novartis AG CAR-T Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.1.4 Novartis AG Main Business Overview
      • 11.1.5 Novartis AG Latest Developments
    • 11.2 Kite Pharma
      • 11.2.1 Kite Pharma Company Information
      • 11.2.2 Kite Pharma CAR-T Therapy Product Offered
      • 11.2.3 Kite Pharma CAR-T Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.2.4 Kite Pharma Main Business Overview
      • 11.2.5 Kite Pharma Latest Developments
    • 11.3 Pfizer
      • 11.3.1 Pfizer Company Information
      • 11.3.2 Pfizer CAR-T Therapy Product Offered
      • 11.3.3 Pfizer CAR-T Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.3.4 Pfizer Main Business Overview
      • 11.3.5 Pfizer Latest Developments
    • 11.4 Juno Therapeutics
      • 11.4.1 Juno Therapeutics Company Information
      • 11.4.2 Juno Therapeutics CAR-T Therapy Product Offered
      • 11.4.3 Juno Therapeutics CAR-T Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.4.4 Juno Therapeutics Main Business Overview
      • 11.4.5 Juno Therapeutics Latest Developments
    • 11.5 Celgene Corporation
      • 11.5.1 Celgene Corporation Company Information
      • 11.5.2 Celgene Corporation CAR-T Therapy Product Offered
      • 11.5.3 Celgene Corporation CAR-T Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.5.4 Celgene Corporation Main Business Overview
      • 11.5.5 Celgene Corporation Latest Developments
    • 11.6 CARsgen Therapeutics
      • 11.6.1 CARsgen Therapeutics Company Information
      • 11.6.2 CARsgen Therapeutics CAR-T Therapy Product Offered
      • 11.6.3 CARsgen Therapeutics CAR-T Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.6.4 CARsgen Therapeutics Main Business Overview
      • 11.6.5 CARsgen Therapeutics Latest Developments
    • 11.7 Sorrento Therapeutics
      • 11.7.1 Sorrento Therapeutics Company Information
      • 11.7.2 Sorrento Therapeutics CAR-T Therapy Product Offered
      • 11.7.3 Sorrento Therapeutics CAR-T Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.7.4 Sorrento Therapeutics Main Business Overview
      • 11.7.5 Sorrento Therapeutics Latest Developments
    • 11.8 Legend Biotech
      • 11.8.1 Legend Biotech Company Information
      • 11.8.2 Legend Biotech CAR-T Therapy Product Offered
      • 11.8.3 Legend Biotech CAR-T Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.8.4 Legend Biotech Main Business Overview
      • 11.8.5 Legend Biotech Latest Developments
    • 11.9 Atara Biotherapeutics
      • 11.9.1 Atara Biotherapeutics Company Information
      • 11.9.2 Atara Biotherapeutics CAR-T Therapy Product Offered
      • 11.9.3 Atara Biotherapeutics CAR-T Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.9.4 Atara Biotherapeutics Main Business Overview
      • 11.9.5 Atara Biotherapeutics Latest Developments
    • 11.10 Aurora Biopharma
      • 11.10.1 Aurora Biopharma Company Information
      • 11.10.2 Aurora Biopharma CAR-T Therapy Product Offered
      • 11.10.3 Aurora Biopharma CAR-T Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.10.4 Aurora Biopharma Main Business Overview
      • 11.10.5 Aurora Biopharma Latest Developments
    • 11.11 Autolus Therapeutics PLC
      • 11.11.1 Autolus Therapeutics PLC Company Information
      • 11.11.2 Autolus Therapeutics PLC CAR-T Therapy Product Offered
      • 11.11.3 Autolus Therapeutics PLC CAR-T Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.11.4 Autolus Therapeutics PLC Main Business Overview
      • 11.11.5 Autolus Therapeutics PLC Latest Developments
    • 11.12 Bluebird
      • 11.12.1 Bluebird Company Information
      • 11.12.2 Bluebird CAR-T Therapy Product Offered
      • 11.12.3 Bluebird CAR-T Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.12.4 Bluebird Main Business Overview
      • 11.12.5 Bluebird Latest Developments
    • 11.13 Carina Biotech
      • 11.13.1 Carina Biotech Company Information
      • 11.13.2 Carina Biotech CAR-T Therapy Product Offered
      • 11.13.3 Carina Biotech CAR-T Therapy Revenue, Gross Margin and Market Share (2018-2023)
      • 11.13.4 Carina Biotech Main Business Overview
      • 11.13.5 Carina Biotech Latest Developments
  • 12 Research Findings and Conclusion

USD 3,660 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.